Cochat P, Schärer K
Unité de Néphrologie Pédiatrique, Hôpital E Herriot, Lyon, France.
Pediatr Nephrol. 1993 Apr;7(2):212-8; discussion 218-9. doi: 10.1007/BF00864408.
Primary hyperoxaluria type 1 (PH1) is a rare recessive autosomal inborn error of glyoxylate metabolism leading to oxalate retention, the first target of which is the kidney. The disease is caused by a defect of the liver-specific peroxisomal enzyme alanine: glyoxylate aminotransferase. Patients with pyridoxine-resistant forms of PH1 usually require organ replacement therapy, i.e. liver transplantation to supply the deficient enzyme and/or kidney transplantation to replace the affected organ. The current experience of the management of PH1 has emphasized two main points: (1) end-stage renal failure must be avoided since it increases dramatically the risk of systemic involvement, (2) the correction of oxalate overproduction and organ overload requires the removal of the host liver. Practical attitudes towards these ideas are difficult to assess and an individualized strategy is therefore required. Isolated kidney transplantation should be limited to adult patients with late-onset and a mild course of the disease. The present experience of combined liver-kidney transplantation was gained mainly in adult patients with severe systemic involvement; the 3-year patient survival rate recently increased to 82%. This figure might be improved if the procedure were performed earlier while the glomerular filtration rate (GFR) is above 25 ml/min per 1.73 m2. Isolated liver transplantation should be considered in carefully selected children with severe forms of pyridoxine-resistance (PH1) before GFR has dropped to less than 30 ml/min per 1.73 m2; it seems to be indicated especially in the presence of a rapid decline of GFR in the preceding year.(ABSTRACT TRUNCATED AT 250 WORDS)
1型原发性高草酸尿症(PH1)是一种罕见的隐性常染色体遗传性乙醛酸代谢缺陷病,可导致草酸盐潴留,其首个受累器官是肾脏。该病由肝脏特异性过氧化物酶体酶丙氨酸:乙醛酸转氨酶缺陷引起。对维生素B6耐药型PH1患者通常需要器官替代治疗,即肝移植以提供缺失的酶和/或肾移植以替换受累器官。目前PH1的治疗经验主要强调两点:(1)必须避免终末期肾衰竭,因为这会显著增加全身受累的风险;(2)纠正草酸盐过度生成和器官负荷过重需要切除宿主肝脏。对这些观点的实际态度难以评估,因此需要个体化策略。单纯肾移植应仅限于成年起病且病程较轻的患者。目前肝肾联合移植的经验主要来自有严重全身受累的成年患者;最近3年患者生存率提高到了82%。如果在肾小球滤过率(GFR)高于每1.73平方米25毫升/分钟时更早地进行该手术,这一数字可能会得到改善。对于严重维生素B6耐药型(PH1)的患儿,在GFR降至每1.73平方米低于30毫升/分钟之前,应仔细选择考虑单纯肝移植;特别是在前一年GFR快速下降的情况下似乎有必要进行。(摘要截选至250词)